INT194945

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.74
First Reported 2006
Last Reported 2007
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 4
Disease Relevance 2.39
Pain Relevance 0

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell adhesion (CD22) plasma membrane (CD22)
Anatomy Link Frequency
B-cells 2
CD22 (Homo sapiens)
Pain Link Frequency Relevance Heat
Paracetamol 8 42.00 Quite Low
Antihistamine 11 40.56 Quite Low
rheumatoid arthritis 22 5.00 Very Low Very Low Very Low
corticosteroid 21 5.00 Very Low Very Low Very Low
tolerance 9 5.00 Very Low Very Low Very Low
methotrexate 7 5.00 Very Low Very Low Very Low
cytokine 5 5.00 Very Low Very Low Very Low
Pain 5 5.00 Very Low Very Low Very Low
cINOD 4 5.00 Very Low Very Low Very Low
Central nervous system 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Lymphatic System Cancer 42 99.22 Very High Very High Very High
Apoptosis 5 93.32 High High
Systemic Lupus Erythematosus 96 88.40 High High
Solid Tumor 3 88.24 High High
Disease 70 87.68 High High
Cancer 6 86.04 High High
Epstein-barr Virus 2 82.96 Quite High
Autoimmune Disease 61 77.88 Quite High
Hodgkin's Disease 10 65.72 Quite High
Lymphopenia 4 50.64 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Its known mechanism of action is believed to be the downregulation of the BCR, with mechanisms of action differing from rituximab (by CD22 phosphorylation and BCR effects via immobilised Ig crosslinking) [18,21].
Phosphorylation (phosphorylation) of CD22
1) Confidence 0.74 Published 2006 Journal Arthritis Res Ther Section Body Doc Link PMC1779377 Disease Relevance 0.50 Pain Relevance 0
Its known mechanisms of action differ from the anti-CD20 monoclonal antibody which depletes very efficiently CD20+ B-cells, rituximab, by CD22 phosphorylation (Carnahan et al 2003) and by affecting BCR (via immobilized immunoglobulin crosslinking), as well as inducing moderate, but significant, ADCC, without showing direct apoptotic or complement-mediated killing (Carnahan et al 2003).
Phosphorylation (phosphorylation) of CD22 in B-cells associated with apoptosis
2) Confidence 0.57 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376077 Disease Relevance 0.85 Pain Relevance 0
The antibody was found to rapidly internalize (107 molecules/min) into CD22-positive lymphoma cells) (Shih et al 1994), and induces CD22 phosphorylation (Carnahan et al 2003).
Phosphorylation (phosphorylation) of CD22 associated with lymphatic system cancer
3) Confidence 0.57 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376077 Disease Relevance 0.77 Pain Relevance 0
In vitro studies demonstrated that epratuzumab binding can induce CD22 phosphorylation [49] , and the current data from this study suggest that epratuzumab could potentially mediate direct pharmacological effects by negatively regulating certain hyperactive B cells.
Phosphorylation (phosphorylation) of CD22 in B cells
4) Confidence 0.52 Published 2006 Journal Arthritis Res Ther Section Body Doc Link PMC1526638 Disease Relevance 0.26 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox